March 2, 2020 / 12:48 PM / a month ago

BRIEF-Merck’S Keytruda Significantly Improved Progression-Free Survival Compared With Brentuximab Vedotin In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

March 2 (Reuters) - Merck & Co Inc:

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL COMPARED WITH BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)

* MERCK - BASED ON INTERIM ANALYSIS BY INDEPENDENT DMC, KEYTRUDA SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS VERSUS BRENTUXIMAB VEDOTIN

* MERCK & CO INC - OTHER DUAL PRIMARY ENDPOINT OF OVERALL SURVIVAL WAS NOT FORMALLY TESTED AT INTERIM ANALYSIS

* MERCK - PHASE 3 KEYNOTE-204 TRIAL EVALUATING KEYTRUDA MET ONE OF ITS DUAL PRIMARY ENDPOINTS OF PROGRESSION-FREE SURVIVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below